Cargando…

Screening for Cushing’s Syndrome in Obese Patients

OBJECTIVES: The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese patients devoid of specific clinical symptoms of Cushing’s syndrome. METHODS: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were included in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiryakioglu, Ozay, Ugurlu, Serdal, Yalin, Serap, Yirmibescik, Sibel, Caglar, Erkan, Yetkin, Demet Ozgil, Kadioglu, Pinar
Formato: Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815288/
https://www.ncbi.nlm.nih.gov/pubmed/20126340
http://dx.doi.org/10.1590/S1807-59322010000100003
_version_ 1782177013504671744
author Tiryakioglu, Ozay
Ugurlu, Serdal
Yalin, Serap
Yirmibescik, Sibel
Caglar, Erkan
Yetkin, Demet Ozgil
Kadioglu, Pinar
author_facet Tiryakioglu, Ozay
Ugurlu, Serdal
Yalin, Serap
Yirmibescik, Sibel
Caglar, Erkan
Yetkin, Demet Ozgil
Kadioglu, Pinar
author_sort Tiryakioglu, Ozay
collection PubMed
description OBJECTIVES: The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese patients devoid of specific clinical symptoms of Cushing’s syndrome. METHODS: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were included in the study. As a first screening step, we measured 24-h urinary free cortisol (UFC). An overnight 1-mg dexamethasone suppression test was also performed on all patients. Urinary free cortisol levels above 100 μg/24 h were considered to be abnormal. Suppression of serum cortisol <1.8 μg/dL after administration of 1 mg dexamethasone was the cut-off point for normal suppression. The suppression of the serum cortisol levels failed in all of the patients. RESULTS: Measured laboratory values were as follows: ACTH, median level 28 pg/ml, interquartile range (IQR) 14–59 pg/ml; fasting glucose, 100 (91–113) mg/dL; insulin, 15.7 (7.57–24.45) mU/ml; fT(4), 1.17 (1.05–1.4) ng/dL; TSH, 1.70 (0.91–2.90) mIU/L; total cholesterol, 209 (170.5–250) mg/dL; LDL-c, 136 (97.7–163) mg/dL; HDL-c, 44 (37.25–50.75) mg/dL; VLDL-c, 24 (17–36) mg/dL; triglycerides, 120.5 (86–165) mg/dL. The median UFC level of the patients was 30 μg/24 h (IQR 16–103). High levels of UFC (>100 μg/24 h) were recorded in 37 patients (24%). Cushing’s syndrome was diagnosed in 14 of the 150 patients (9.33%). Etiologic reasons for Cushing’s syndrome were pituitary microadenoma (9 patients), adrenocortical adenoma (3 patients), and adrenocortical carcinoma (1 patient). CONCLUSION: A significant proportion (9.33%) of patients with simple obesity were found to have Cushing’s syndrome. These findings argue that obese patients should be routinely screened for Cushing’s syndrome.
format Text
id pubmed-2815288
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-28152882010-02-02 Screening for Cushing’s Syndrome in Obese Patients Tiryakioglu, Ozay Ugurlu, Serdal Yalin, Serap Yirmibescik, Sibel Caglar, Erkan Yetkin, Demet Ozgil Kadioglu, Pinar Clinics (Sao Paulo) Clinical Science OBJECTIVES: The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese patients devoid of specific clinical symptoms of Cushing’s syndrome. METHODS: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were included in the study. As a first screening step, we measured 24-h urinary free cortisol (UFC). An overnight 1-mg dexamethasone suppression test was also performed on all patients. Urinary free cortisol levels above 100 μg/24 h were considered to be abnormal. Suppression of serum cortisol <1.8 μg/dL after administration of 1 mg dexamethasone was the cut-off point for normal suppression. The suppression of the serum cortisol levels failed in all of the patients. RESULTS: Measured laboratory values were as follows: ACTH, median level 28 pg/ml, interquartile range (IQR) 14–59 pg/ml; fasting glucose, 100 (91–113) mg/dL; insulin, 15.7 (7.57–24.45) mU/ml; fT(4), 1.17 (1.05–1.4) ng/dL; TSH, 1.70 (0.91–2.90) mIU/L; total cholesterol, 209 (170.5–250) mg/dL; LDL-c, 136 (97.7–163) mg/dL; HDL-c, 44 (37.25–50.75) mg/dL; VLDL-c, 24 (17–36) mg/dL; triglycerides, 120.5 (86–165) mg/dL. The median UFC level of the patients was 30 μg/24 h (IQR 16–103). High levels of UFC (>100 μg/24 h) were recorded in 37 patients (24%). Cushing’s syndrome was diagnosed in 14 of the 150 patients (9.33%). Etiologic reasons for Cushing’s syndrome were pituitary microadenoma (9 patients), adrenocortical adenoma (3 patients), and adrenocortical carcinoma (1 patient). CONCLUSION: A significant proportion (9.33%) of patients with simple obesity were found to have Cushing’s syndrome. These findings argue that obese patients should be routinely screened for Cushing’s syndrome. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2010-01 /pmc/articles/PMC2815288/ /pubmed/20126340 http://dx.doi.org/10.1590/S1807-59322010000100003 Text en Copyright © 2010 Hospital das Clínicas da FMUSP
spellingShingle Clinical Science
Tiryakioglu, Ozay
Ugurlu, Serdal
Yalin, Serap
Yirmibescik, Sibel
Caglar, Erkan
Yetkin, Demet Ozgil
Kadioglu, Pinar
Screening for Cushing’s Syndrome in Obese Patients
title Screening for Cushing’s Syndrome in Obese Patients
title_full Screening for Cushing’s Syndrome in Obese Patients
title_fullStr Screening for Cushing’s Syndrome in Obese Patients
title_full_unstemmed Screening for Cushing’s Syndrome in Obese Patients
title_short Screening for Cushing’s Syndrome in Obese Patients
title_sort screening for cushing’s syndrome in obese patients
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815288/
https://www.ncbi.nlm.nih.gov/pubmed/20126340
http://dx.doi.org/10.1590/S1807-59322010000100003
work_keys_str_mv AT tiryakiogluozay screeningforcushingssyndromeinobesepatients
AT ugurluserdal screeningforcushingssyndromeinobesepatients
AT yalinserap screeningforcushingssyndromeinobesepatients
AT yirmibesciksibel screeningforcushingssyndromeinobesepatients
AT caglarerkan screeningforcushingssyndromeinobesepatients
AT yetkindemetozgil screeningforcushingssyndromeinobesepatients
AT kadioglupinar screeningforcushingssyndromeinobesepatients